Gritstone bio Inc. (NASDAQ: GRTS) is -74.73% lower on its value in year-to-date trading and has touched a low of $1.71 and a high of $14.42 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The GRTS stock was last observed hovering at around $3.18 in the last trading session, with the day’s gains setting it 0.07% off its average median price target of $6.50 for the next 12 months. It is also 83.75% off the consensus price target high of $20.00 offered by 5 analysts, but current levels are -62.5% lower than the price target low of $2.00 for the same period.
Currently trading at $3.25, the stock is 11.36% and 17.69% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 0.43 million and changing 2.20% at the moment leaves the stock 0.98% off its SMA200. GRTS registered -68.07% loss for a year compared to 6-month gain of 83.62%.
The stock witnessed a 32.65% loss in the last 1 month and extending the period to 3 months gives it a -7.67%, and is -0.31% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 9.37% over the week and 11.37% over the month.
Gritstone bio Inc. (GRTS) has around 201 employees, a market worth around $274.98M and $18.70M in sales. Distance from 52-week low is 90.06% and -77.46% from its 52-week high. The company has generated returns on investments over the last 12 months (-34.80%).
Gritstone bio Inc. (GRTS) Analyst Forecasts
Analyst recommendations provided by FactSet shows that the consensus forecast for Gritstone bio Inc. (GRTS) is a “Overweight”. 5 analysts offering their recommendations for the stock have an average rating of 2.20, where 0 rate it as a Hold and 0 think it is a “Overweight”. 4 of the analysts rate the stock as a “Buy”. 1 analysts have rated the stock as a Sell or Underperform.
Gritstone bio Inc. is expected to release its quarterly report on 03/09/2023.The EPS is expected to grow by 65.80% this year
Gritstone bio Inc. (GRTS) Top Institutional Holders
The shares outstanding are 86.60M, and float is at 81.20M with Short Float at 7.14%.
Gritstone bio Inc. (GRTS) Insider Activity
A total of 0 insider transactions have happened at Gritstone bio Inc. (GRTS) in the last six months, with sales accounting for 0 and purchases happening 0 times. The most recent transaction is an insider sale by Jones Erin, the company’s Chief Operating Officer. SEC filings show that Jones Erin sold 1,000 shares of the company’s common stock on Dec 01 at a price of $13.01 per share for a total of $13010.0. Following the sale, the insider now owns 45900.0 shares.
Gritstone bio Inc. (GRTS): Who are the competitors?
The company’s main competitors (and peers) include Eli Lilly and Company (LLY) that is trading 38.08% up over the past 12 months and Merck & Co. Inc. (MRK) that is 29.01% higher over the same period. Moderna Inc. (MRNA) is -36.03% down on the 1-year trading charts.